Compare

BPC-157 vs TB-500

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

99 users report co-tracking this pair (4% of BPC-157 trackers also track TB-500).

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

BPC-157

126 community reports

Positive 98% · Neutral 2% · Negative 0%

Most reported benefits

Recovery
245

Most reported side effects

Nausea
5

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
2
25–50
1
50–100
0
100–200
3
200–400
138
400–600
93
600–1000
5
1000–2000
1
2000+
2

How repeat users are trending

Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 50 days · Based on 47 repeat reporters

TB-500

103 community reports

Positive 38% · Neutral 62% · Negative 0%

Most reported benefits

Recovery
219

Most reported side effects

Headache
70
Fatigue
65

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
14
25–50
1
50–100
0
100–200
1
200–400
29
400–600
25
600–1000
2
1000–2000
5
2000+
142

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 23% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 63 days · Based on 40 repeat reporters